Review article: diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
01
09
2021
received:
10
08
2021
accepted:
18
05
2022
pubmed:
4
6
2022
medline:
14
7
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
Persistent abdominal pain (PAP) poses substantial challenges to patients, physicians and healthcare systems. The possible aetiologies of PAP vary widely across organ systems, which leads to extensive and repetitive diagnostic testing that often fails to provide satisfactory answers. As a result, widely recognised functional disorders of the gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia, are often diagnosed in patients with PAP. However, there are a number of less well-known differential diagnoses that deserve consideration. To provide a comprehensive update on causes of PAP that are relatively rare in occurrence. A literature review on the diagnosis and management of some less well-known causes of PAP. Specific algorithms for the diagnostic work-up of PAP do not exist. Instead, appropriate investigations tailored to patient medical history and physical examination findings should be made on a case-by-case basis. After a definitive diagnosis has been reached, some causes of PAP can be effectively treated using established approaches. Other causes are more complex and may benefit from a multidisciplinary approach involving gastroenterologists, pain specialists, psychologists and physiotherapists. This list is inclusive but not exhaustive of all the rare or less well-known diseases potentially associated with PAP. Persistent abdominal pain (PAP) is a challenging condition to diagnose and treat. Many patients undergo repeated diagnostic testing and treatment, including surgery, without achieving symptom relief. Increasing physician awareness of the various causes of PAP, especially of rare diseases that are less well known, may improve patient outcomes.
Sections du résumé
BACKGROUND
Persistent abdominal pain (PAP) poses substantial challenges to patients, physicians and healthcare systems. The possible aetiologies of PAP vary widely across organ systems, which leads to extensive and repetitive diagnostic testing that often fails to provide satisfactory answers. As a result, widely recognised functional disorders of the gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia, are often diagnosed in patients with PAP. However, there are a number of less well-known differential diagnoses that deserve consideration.
AIM
To provide a comprehensive update on causes of PAP that are relatively rare in occurrence.
METHODS
A literature review on the diagnosis and management of some less well-known causes of PAP.
RESULTS
Specific algorithms for the diagnostic work-up of PAP do not exist. Instead, appropriate investigations tailored to patient medical history and physical examination findings should be made on a case-by-case basis. After a definitive diagnosis has been reached, some causes of PAP can be effectively treated using established approaches. Other causes are more complex and may benefit from a multidisciplinary approach involving gastroenterologists, pain specialists, psychologists and physiotherapists. This list is inclusive but not exhaustive of all the rare or less well-known diseases potentially associated with PAP.
CONCLUSIONS
Persistent abdominal pain (PAP) is a challenging condition to diagnose and treat. Many patients undergo repeated diagnostic testing and treatment, including surgery, without achieving symptom relief. Increasing physician awareness of the various causes of PAP, especially of rare diseases that are less well known, may improve patient outcomes.
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-435Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Tolba R, Shroll J, Kanu A, Rizk MK. The epidemiology of chronic abdominal pain. In: Kapural L, editor. Chronic abdominal pain. New York, NY: Springer; 2015. p. 13-24.
Lakhoo K, Almario CV, Khalil C, Spiegel BMR. Prevalence and characteristics of abdominal pain in the United States. Clin Gastroenterol Hepatol. 2021;19(9):1864-72.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262-79.
van Dulmen AM, Fennis JF, Mokkink HG, van der Velden HG, Bleijenberg G. Doctors' perception of patients' cognitions and complaints in irritable bowel syndrome at an out-patient clinic. J Psychosom Res. 1994;38(6):581-90.
Van Dulmen AM, Fennis JF, Mokkink HG, Van der Velden HG, Bleijenberg G. Doctor-dependent changes in complaint-related cognitions and anxiety during medical consultations in functional abdominal complaints. Psychol Med. 1995;25(5):1011-8.
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014.
Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G, et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3:17081.
Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46(1):78-82.
Bhatt A, Stevens T. Establishing diagnosis of chronic abdominal pain: gastroenterologist view. In: Kapural L, editor. Chronic abdominal pain. New York, NY: Springer; 2015. p. 25-32.
Veizi IE, Wynne M, Hayek SM. Establishing diagnosis of chronic abdominal pain: pain medicine view. In: Kapural L, editor. Chronic abdominal pain. New York, NY: Springer; 2015. p. 33-43.
Coffin B, Sabate JM, Jouet P. Persistent abdominal pain. Gastroenterol Clin Biol. 2006;30(3):392-8.
Bharucha AE, Chakraborty S, Sletten CD. Common functional gastroenterological disorders associated with abdominal pain. Mayo Clin Proc. 2016;91(8):1118-32.
Keefer L, Drossman DA, Guthrie E, Simrén M, Tillisch K, Olden K, et al. Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016;150(6):1408-19.
Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut. 2004;53(5):666-72.
Pourmand H, Esmaillzadeh A. Consumption of a low fermentable oligo-, di-, mono-saccharides, and polyols diet and irritable bowel syndrome: a systematic review. Int J Prev Med. 2017;8:104.
Kilgallon E, Vasant DH, Green D, Shields PL, Hamdy S, Lal S, et al. Chronic continuous abdominal pain: evaluation of diagnostic features, iatrogenesis and drug treatments in a cohort of 103 patients. Aliment Pharmacol Ther. 2019;49(10):1282-92.
Eriksson EM, Andren KI, Kurlberg GK, Eriksson HT. Aspects of the non-pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2015;21(40):11439-49.
Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004;126(7):1665-73.
Ringel-Kulka T, Ringel Y. Evaluation of chronic abdominal pain. BMJ Best Pract. 2021;1-41.
Sunkara T, Rawla P, Yarlagadda KS, Gaduputi V. Eosinophilic gastroenteritis: diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2019;12:239-53.
Hussein MR, Abdelwahed SR. Mesenteric panniculitis: an update. Expert Rev Gastroenterol Hepatol. 2015;9(1):67-78.
Barret M, Martineau C, Rahmi G, Pellerin O, Sapoval M, Alsac JM, et al. Chronic mesenteric ischemia: a rare cause of chronic abdominal pain. Am J Med. 2015;128(12):1363.e1361-8.
Patel R, Waheed A, Costanza M. Chronic mesenteric ischemia. Treasure Island, FL: StatPearls Publishing; 2021.
Terlouw LG, Moelker A, Abrahamsen J, Acosta S, Bakker OJ, Baumgartner I, et al. European guidelines on chronic mesenteric ischaemia-joint united European gastroenterology, European Association for Gastroenterology, endoscopy and nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, cardiovascular and interventional radiological Society of Europe, and Dutch mesenteric ischemia study group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia. United European Gastroenterol J. 2020;8(4):371-95.
van Dijk LJ, van Noord D, de Vries AC, et al. Clinical management of chronic mesenteric ischemia. United European Gastroenterol J. 2019;7(2):179-88.
Goodall R, Langridge B, Onida S, Ellis M, Lane T, Davies AH. Median arcuate ligament syndrome. J Vasc Surg. 2020;71(6):2170-6.
Gerner-Rasmussen J, Burcharth J, Gogenur I. The efficacy of adhesiolysis on chronic abdominal pain: a systematic review. Langenbecks Arch Surg. 2015;400(5):567-76.
Paajanen P, Fagerstrom A, Paajanen H. Laparoscopic adhesiolysis in chronic abdominal pain: 15-year follow-up study. J Clin Gastroenterol. 2018;52(4):e32-6.
Molegraaf MJ, Torensma B, Lange CP, Lange JF, Jeekel J, Swank DJ. Twelve-year outcomes of laparoscopic adhesiolysis in patients with chronic abdominal pain: a randomized clinical trial. Surgery. 2017;161(2):415-21.
Cotton PB, Elta GH, Carter CR, Pasricha PJ, Corazziari ES. Gallbladder and sphincter of Oddi disorders. Gastroenterology 2016;150:1420-9
Bistritz L, Bain VG. Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain. World J Gastroenterol. 2006;12(24):3793-802.
Sweetser S. Abdominal wall pain: a common clinical problem. Mayo Clin Proc. 2019;94(2):347-55.
Shian B, Larson ST. Abdominal wall pain: clinical evaluation, differential diagnosis, and treatment. Am Fam Physician. 2018;98(7):429-36.
Koop H, Koprdova S, Schurmann C. Chronic abdominal wall pain. Dtsch Arztebl Int. 2016;113(4):51-7.
Kamboj AK, Hoversten P, Oxentenko AS. Chronic abdominal wall pain: a common yet overlooked etiology of chronic abdominal pain. Mayo Clin Proc. 2019;94(1):139-44.
Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. Lancet. 2021;397(10274):613-29.
Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152-67.
Afrin LB, Ackerley MB, Bluestein LS, Brewer JH, Brook JB, Buchanan AD, et al. Diagnosis of mast cell activation syndrome: a global "consensus-2". Diagnosis (Berlin, Germany). 2021;8(2):137-52.
Weinstock LB, Pace LA, Rezaie A, Afrin LB, Molderings GJ. Mast cell activation syndrome: a primer for the gastroenterologist. Dig Dis Sci. 2021;66(4):965-82.
Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci. 2020;21(23):9030.
Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1121.
Ramsay DB, Stephen S, Borum M, Voltaggio L, Doman DB. Mast cells in gastrointestinal disease. Gastroenterol Hepatol. 2010;6(12):772-7.
Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-7.
Systemic mastocytosis. 2019. https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=887&Disease_Disease_Search_diseaseGroup=systemic-mastocytosis&%E2%80%A6. Accessed January 18, 2022
Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(9):862-72.
Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549-58.
Tatari MM, McCain JD, Cowdell JC. 28-year-old woman with severe generalized abdominal pain. Mayo Clin Proc. 2019;94(7):1334-8.
Guerrero RB, Kloke KM, Salazar D. Inborn errors of metabolism and the gastrointestinal tract. Gastroenterol Clin North Am. 2019;48(2):183-98.
Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289-301.
Wani AL, Ara A, Usmani JA. Lead toxicity: a review. Interdiscip Toxicol. 2015;8(2):55-64.
Marginean CO, Melit LE, Moldovan H, Lupu VV, Marginean MO. Lead poisoning in a 16-year-old girl: a case report and a review of the literature (CARE compliant). Medicine. 2016;95(38):e4916.
Frank M, Adham S, Zinzindohoue F, Jeunemaitre X. Natural history of gastrointestinal manifestations in vascular Ehlers-Danlos syndrome: a 17-year retrospective review. J Gastroenterol Hepatol. 2019;34(5):857-63.
Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):181-7.
Botrus G, Baker O, Borrego E, Ngamdu KS, Teleb M, Gonzales Martinez JL, et al. Spectrum of gastrointestinal manifestations in joint hypermobility syndromes. Am J Med Sci. 2018;355(6):573-80.
Goubault P, Brunel T, Rode A, Bancel B, Mohkam K, Mabrut JY. Low-phospholipid associated cholelithiasis (LPAC) syndrome: a synthetic review. J Visc Surg. 2019;156(4):319-28.
Sonmez HE, Batu ED, Ozen S. Familial Mediterranean fever: current perspectives. J Inflamm Res. 2016;9:13-20.
Ozen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253.
Familial Mediterranean Fever Statistics. 2020. https://ghr.nlm.nih.gov/condition/familial-mediterranean-fever#statistics. Accessed January 18, 2022.
DiBaise JK, Harris LA, Goodman B. Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol. 2018;113(10):1458-67.
Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273-97.
Farmer AD, Gallagher J, Bruckner-Holt C, Aziz Q. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017;2(5):361-8.
Azizi Z, Javid Anbardan S, Ebrahimi DN. A review of the clinical manifestations, pathophysiology and management of opioid bowel dysfunction and narcotic bowel syndrome. Middle East J Dig Dis. 2014;6(1):5-12.
Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63.
Maddern J, Grundy L, Castro J, Brierley SM. Pain in endometriosis. Front Cell Neurosci. 2020;14:590823.
Ek M, Roth B, Ekström P, Valentin L, Bengtsson M, Ohlsson B. Gastrointestinal symptoms among endometriosis patients-a case-cohort study. BMC Womens Health. 2015;15:59.
Gruber TM, Mechsner S. Pathogenesis of endometriosis: the origin of pain and subfertility. Cell. 2021;10(6):1381.
Nzeako UC. Diagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective. World J Gastroenterol. 2010;16(39):4913-21.
Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619-27.
Gower RG, Busse PJ, Aygören-Pürsün E, Barakat AJ, Caballero T, Davis-Lorton M, et al. Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J. 2011;4(2 suppl):S9-S21.
Srinivasan R, Greenbaum DS. Chronic abdominal wall pain: a frequently overlooked problem. Practical approach to diagnosis and management. Am J Gastroenterol. 2002;97(4):824-30.
Swank DJ, Swank-Bordewijk SC, Hop WC, van Erp W, Janssen IMC, Bonjer HJ, et al. Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-Centre trial. Lancet. 2003;361(9365):1247-51.
McGarrity TJ, Peters DJ, Thompson C, McGarrity SJ. Outcome of patients with chronic abdominal pain referred to chronic pain clinic. Am J Gastroenterol. 2000;95(7):1812-6.
Costanza CD, Longstreth GF, Liu AL. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol. 2004;2(5):395-9.
Lindsetmo RO, Stulberg J. Chronic abdominal wall pain-a diagnostic challenge for the surgeon. Am J Surg. 2009;198(1):129-34.
van Assen T, Boelens OB, Kamphuis JT, Scheltinga MR, Roumen RM. Construction and validation of a questionnaire distinguishing a chronic abdominal wall pain syndrome from irritable bowel syndrome. Frontline Gastroenterol. 2012;3(4):288-94.
Sellman MS, Mayer RF. Thoracoabdominal radiculopathy. South Med J. 1988;81(2):199-201.
Quénéhervé L, Drui D, Blin J, Péré M, Coron E, Barbara G, et al. Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms. Sci Rep. 2021;11(1):8077.
Desramé J, Sabaté JM, Agher R, Bremont C, Gaudric M, Couturier D, et al. Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. Am J Gastroenterol. 2002;97(7):1785-91.
Wilder-Smith CH, Drewes AM, Materna A, Olesen SS. Symptoms of mast cell activation syndrome in functional gastrointestinal disorders. Scand J Gastroenterol. 2019;54(11):1322-5.
Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2(1):70-6.
Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349-55.
Giannetti A, Filice E, Caffarelli C, Ricci G, Pession A. Mast cell activation disorders. Medicina. 2021;57:124.
Frieri M. Mast cell activation syndrome. Clin Rev Allergy Immunol. 2018;54(3):353-65.
Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in long-COVID. Int J Infect Dis. 2021;112:217-26.
Ratner M. Patients with porphyria bask in sunlight of FDA approval. Nat Biotechnol. 2019;37(12):1390-1.
Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233-41.
Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stölzel U, et al. EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks. Hepatology. 2020;71(5):1546-58.
Woolf J, Marsden JT, Degg T, Whatley S, Reed P, Brazil N, et al. Best practice guidelines on first-line laboratory testing for porphyria. Ann Clin Biochem. 2017;54(2):188-98.
Ruckart PZ, Ettinger AS, Hanna-Attisha M, Jones N, Davis SI, Breysse PN. The Flint water crisis: a coordinated public health emergency response and recovery initiative. J Public Health Manag Pract. 2019;25(suppl 1, Lead Poisoning Prevention):S84-S90.
Alnylam announces approval of GIVLAARI® (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults. [press release] 2020. https://investors.alnylam.com/sites/default/files/GIVLAARI-Brazil-Approval-Press-Release.pdf. Accessed January 18, 2022.
Givlaari [package insert]. Cambridge, MA: Alnylam Pharmaceuticals; 2021.
Givlaari [summary of product characteristics]. 2021. https://www.ema.europa.eu/en/documents/product-information/givlaari-epar-product-information_en.pdf. Accessed January 18, 2022.
Givlaari Canada [product monograph]. Amsterdam, Netherlands: Alnylam Netherlands; 2020.
Obtained manufacturing and marketing approval for "Giblari" for the treatment of acute hepatic porphyria [press release]. 2021. https://www.alnylam.jp/sites/default/files/news-articles/Japan_Givo_Approval_Press_Release_0.pdf. Accessed January 18, 2022.
Nelson AD, Mouchli MA, Valentin N, Deyle D, Pichurin P, Acosta A, et al. Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. Neurogastroenterol Motil. 2015;27(11):1657-66.
Zeitoun JD, Lefevre JH, de Parades V, et al. Functional digestive symptoms and quality of life in patients with Ehlers-Danlos syndromes: results of a national cohort study on 134 patients. PloS ONE. 2013;8(11):e80321.
Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos support group (UK). Am J Med Genet. 1998;77(1):31-7.
Fikree A, Aktar R, Grahame R, Hakim AJ, Morris JK, Knowles CH, et al. Functional gastrointestinal disorders are associated with the joint hypermobility syndrome in secondary care: a case-control study. Neurogastroenterol Motil. 2015;27(4):569-79.
Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26.
Castori M, Morlino S, Pascolini G, Blundo C, Grammatico P. Gastrointestinal and nutritional issues in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet C Semin Med Genet. 2015;169c:54-75.
Lam CY, Palsson OS, Whitehead WE, Sperber AD, Tornblom H, Simren M, et al. Rome IV functional gastrointestinal disorders and health impairment in subjects with hypermobility spectrum disorders or hypermobile Ehlers-Danlos syndrome. Clin Gastroenterol Hepatol. 2021;19(2):277-287.e273.
Reinstein E, Pimentel M, Pariani M, Nemec S, Sokol T, Rimoin DL. Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literature. Eur J Med Genet. 2012;55(10):548-51.
Mercan R, Bitik B, Eren R, Dumludag B, Turan A, Kucuk H, et al. Underlying causes of persistently elevated acute phase reactants in patiens with familial Mediterranean fever [abstract]. Pediatr Rheumatol. 2015;13(1):P139.
Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127(23):2336-42.
Kurlander JE, Drossman DA. Diagnosis and treatment of narcotic bowel syndrome. Nat Rev Gastroenterol Hepatol. 2014;11(7):410-8.
Kim SE, Chang L. Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil. 2012;24(10):895-913.